Abiratas (Abiraterone Acetate) [+cityin+]

DESCRIPTION

Abiratas is belongs to anti neoplastic drugs which will work by Diminish the androgen production in the body. Androgen is a male hormone which balances the cancer cell in prostate glands.

Normaly this tablet is taken by combination with prednisolone, a steroid which decreases the liability of side effects produced by Abiraterone.

MECHANISM OF ACTION

Androgens are regulates the production of tumors in prostate. Abiratas is an anti androgen drugs, which causes to eradicate the enzyme 17α-hydroxylase C 17, 20-lyase CYP17), it is includes in androgen synthesis. Decrease the serum testosterone level. Diminished the tumor cell occurred.

PHARMACOKINETIC

Absorption

Time to median plasma concentration of tablet Abiratas takes 12 hours.

Distribution

Maximum bound to the human plasma protein like albumin and alpha-1 acid glycoprotein.

Metabolism

The main two metabolites of Abiraterone in human plasma are Abiraterone sulphate and N-oxide Abiraterone sulphate.

Elimination

Terminal half life of tablet Abiratas is 12 ± 5 hours. The drug mainly excreted in 88% feces and 5% in urine.

DOSAGE MANAGEMENT

The usual dose of Abiratas is endorsed as 4 tablets orally once daily The drug Abiratas given with 5mg prednisolone twice daily in empty stomach. Abiratas Tablets administrated on an empty stomach. No food should be consumed for at least 2 hours before and at least 1 hour after the dose of Abiratas Tablets is taken. Abiratas should be swallowed whole with water. Do not crush or chew the tablets.

OVERDOSAGE

Abiratas has no specific antitoxin, If overdose occurs stop the drug and provide general supportive measures such as monitoring arrhythmias and cardiac failure and assess liver function.

SIDE EFFECTS

Common effects

Fatigue, Arthralgia, Hypertension, Nausea, edema, Hypokalemia, Diarrhea, vomiting, Cough, headache, Glucocorticoid deficiency, Mineral corticoid deficiency Hepatotoxicity Hypertension, Decrease in ka level Adrenocortical insufficiency

Musculo skeletal and Connective tissue disorders

Joint swelling, discomfort, muscle discomfort

General Disorder

Oedema

Cardiac disorders

Hot flush, hypertension, arrhythmias, chest pain, cardiac failure

GIT disorders

Diarrhea, dyspepsia

Infections and Infestation

UTI

Pulmonary disorder

Cough

Renal

Urinary frequency, nocturia

Injuries

Fractures

DRUG INTERACTION

Abiratas interaction with dextromethorphan will increases the Cmax and AUC of dextromethorphan Abiratas interaction with strong CYP3A inhibitors or inducers , use combination with caution because pharmacokinetics is not evaluated.

PRECAUTION

If patient having any allergy, severe liver problem, or pregnant, Abiratas tablet should be discontinued Do not take other medications, i.e prescription, over-the-counter, vitamins, herbal remedies, etc be sure to inform the doctors before the treatment. Aspirin do not administering and products containing aspirin till doctor particularly allow the drug.

PREGNANCY

pregnancy category X (leads to fetal death): During treatment if women become pregnant, immediately stop the drug and give counseling to the women. Abiratas tablet is not recommended for women.

LACTATION

Abiratas is not used in women excretion in human milk is unknown and the drug effects in the nursing infant is unknown.

STORAGE

Stored at 15°C-30°C in a dry place.

MISSED DOSE

If patient missed the dose of Abiratas, that missed dose will be skipped and follow the regular dosing schedule.